DDInter932 DDInter704
Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin glargine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Lipoic acid {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin glargine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin glargine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phentolamine
Phentolamine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Insulin glargine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Potassium chloride
Potassium chloride {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethionamide
Ethionamide {u} (Compound) upregulates {v} (Gene) ZNF586
ZNF586 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid (Compound) binds POR (Gene) and POR (Gene) is upregulated by Everolimus (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Everolimus (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Everolimus (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Everolimus (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide and Ethionamide (Compound) upregulates ZNF586 (Gene) and ZNF586 (Gene) is downregulated by Everolimus (Compound)